Prognostic significance of XIAP and NF-κB expression in esophageal carcinoma with postoperative radiotherapy

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Zhou, Suna ^a   Ye, Wenguang ^a   Shao, Qiuju ^a   Qi, Yuhong ^a   Zhang, Mingxin ^a   Liang, Jun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; Nuclear factor B; X chromosome linked IAP

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR DIFFERENTIATION;

CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NF-KAPPA B; PROGNOSIS; SURVIVAL RATE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84887077816     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-288     Document Type: Article

References (33)

1. Hiyama T, Yoshihara M, Tanaka S, Chayama K. Genetic polymorphisms and esophageal cancer risk. Int J Cancer 2007, 121(8):1643-1658. 10.1002/ijc.23044, 17674367.
2. Yuequan J, Shifeng C, Bing Z. Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery. Ann Thorac Surg 2010, 90(3):908-913. 10.1016/j.athoracsur.2010.05.060, 20732516.
3. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004, 198(2):205-211. 10.1016/j.jamcollsurg.2003.10.005, 14759776.
4. Miyazaki T, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, Masuda N, Manda R, Fukuchi M, Ojima H, Tsukada K, Kuwano H. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res 2005, 25(4):2749-2755.
5. Li BZ, Chen ZL, Shi SS, Feng XL, Tan XG, Zhou F, He J. Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery. Chin J Cancer 2013, doi:10.5732/cjc.012.10233. [Epub ahead of print].
6. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012, 11(2):109-124. 10.1038/nrd3627, 22293567.
7. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006, 7(10):988-994. 10.1038/sj.embor.7400795, 1618369, 17016456.
8. Vucic D. Targeting IAP, (inhibitor of apoptosis) proteins for therapeutic intervention in tumors. Curr Cancer Drug Targets 2008, 8(2):110-117. 10.2174/156800908783769373, 18336193.
9. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000, 60(20):5659-5666.
10. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003, 9(7):2826-2836.
11. Bilim V, Kasahara T, Hara N, Takahashi K, Tomita Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 2003, 103(1):29-37. 10.1002/ijc.10776, 12455050.
12. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, Morris SJ, Durkin JP, Lacasse EC. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004, 23(49):8105-8117. 10.1038/sj.onc.1207967, 15378029.
13. Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S, Liu Z, Zhang L. XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther 2007, 6(6):973-980.
14. Ohnishi K, Scuric Z, Schiestl RH, Okamoto N, Takahashi A, Ohnishi T. siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status. Radiat Res 2006, 166(3):454-462. 10.1667/RR3606.1, 16972754.
15. Kim DW, Seo SW, Cho SK, Chang SS, Lee HW, Lee SE, Block JA, Hei TK, Lee FY. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. J Orthop Res 2007, 25(6):820-828. 10.1002/jor.20377, 17343283.
16. Giagkousiklidis S, Vellanki SH, Debatin KM, Fulda S. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007, 26(49):7006-7016. 10.1038/sj.onc.1210502, 17471230.
17. Wang R, Li B, Wang X, Lin F, Gao P, Cheng SY, Zhang HZ. Inhibiting XIAP expression by RNAi to inhibit proliferation and enhance radiosensitivity in laryngeal cancer cell line. Auris Nasus Larynx 2009, 36(3):332-339. 10.1016/j.anl.2008.08.006, 19013033.
18. Connolly K, Mitter R, Muir M, Jodrell D, Guichard S. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemother Pharmacol 2009, 64(2):307-316. 10.1007/s00280-008-0872-x, 19034449.
19. Moussata D, Amara S, Siddeek B, Decaussin M, Hehlgans S, Paul-Bellon R, Mornex F, Gerard JP, Romestaing P, Rödel F, Flourie B, Benahmed M, Mauduit C. XIAP as a radioresistance factor and prognostic marker for radiotherapy in human rectal adenocarcinoma. Am J Pathol 2012, 181(4):1271-1278. 10.1016/j.ajpath.2012.06.029, 22867709.
20. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci 2005, 1056:218-233. 10.1196/annals.1352.026, 16387690.
21. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005, 446(5):475-482. 10.1007/s00428-005-1264-9, 15856292.
22. Lu M, Lin SC, Huang Y, Kang YJ, Rich R, Lo YC, Myszka D, Han J, Wu H. XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 2007, 26(5):689-702. 10.1016/j.molcel.2007.05.006, 1991276, 17560374.
23. Hatata T, Higaki K, Tatebe S, Shomori K, Ikeguchi M. Immunohistochemical study of nuclear factor-κB expression in esophageal squamous cell carcinoma: prognostic significance and sensitivity to treatment with 5-FU. Dis Esophagus 2012, 25(8):716-722. 10.1111/j.1442-2050.2011.01308.x, 22292507.
24. Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, Gu XZ, Zhang DC, Zhang RG, Wang LJ. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg 2003, 75(2):331-336. 10.1016/S0003-4975(02)04401-6, 12607634.
25. Chen J, Zhu J, Pan J, Zhu K, Zheng X, Chen M, Wang J, Liao Z. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus. Ann Thorac Surg 2010, 90(2):435-442. 10.1016/j.athoracsur.2010.04.002, 20667325.
26. Chen J, Pan J, Zheng X, Zhu K, Li J, Chen M, Wang J, Liao Z. Number and location of positive nodes, postoperative radiotherapy, and survival after esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2012, 82(1):475-482. 10.1016/j.ijrobp.2010.08.037, 20934269.
27. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, Simmet T, Debatin KM, Fulda S. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009, 69(6):2425-2434. 10.1158/0008-5472.CAN-08-2436, 19258513.
28. Cao C, Mu Y, Hallahan DE, Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004, 23(42):7047-7052. 10.1038/sj.onc.1207929, 15258565.
29. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, Boeckers T, Debatin KM, Fulda S. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009, 11(8):743-752. 2713593, 19649204.
30. Ohnishi K, Nagata Y, Takahashi A, Taniguchi S, Ohnishi T. Effective enhancement of X-ray-induced apoptosis in human cancer cells with mutated p53 by siRNA targeting XIAP. Oncol Rep 2008, 20(1):57-61.
31. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010, 10(8):561-574. 10.1038/nrc2889, 20651737.
32. Ramp U, Krieg T, Caliskan E, Mahotka C, Ebert T, Willers R, Gabbert HE, Gerharz CD. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 2004, 35(8):1022-1028. 10.1016/j.humpath.2004.03.011, 15297970.
33. Li M, Song T, Yin ZF, Na YQ. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin Med J (Engl) 2007, 120(6):469-473.